| Dr Vincent Falanga, MD | |
|
725 Albany St # 8b, Shapiro Bldg., Boston, MA 02118-2526 | |
| (617) 638-7420 | |
| (617) 638-7289 |
| Full Name | Dr Vincent Falanga |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 47 Years |
| Location | 725 Albany St # 8b, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376501825 | NPI | - | NPPES |
| 9025375 | Medicaid | RI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.
Children and adolescents with epilepsy experience significant long-term socioeconomic consequences and higher personal health care costs. The findings come from a study that followed young epilepsy patients until 30 years of age
There's nothing more frightening than hearing the words "you have cancer" from your physician. With this diagnosis, many questions come to mind ... What's next? Will I survive? How do I tell my loved ones? The last is the most important for many people after receiving a cancer diagnosis: I need accurate information right now.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases, with total funding up to more than $200 million over seven years if all contract options are exercised.
› Verified 8 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.
Children and adolescents with epilepsy experience significant long-term socioeconomic consequences and higher personal health care costs. The findings come from a study that followed young epilepsy patients until 30 years of age
There's nothing more frightening than hearing the words "you have cancer" from your physician. With this diagnosis, many questions come to mind ... What's next? Will I survive? How do I tell my loved ones? The last is the most important for many people after receiving a cancer diagnosis: I need accurate information right now.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases, with total funding up to more than $200 million over seven years if all contract options are exercised.
› Verified 8 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.
Children and adolescents with epilepsy experience significant long-term socioeconomic consequences and higher personal health care costs. The findings come from a study that followed young epilepsy patients until 30 years of age
There's nothing more frightening than hearing the words "you have cancer" from your physician. With this diagnosis, many questions come to mind ... What's next? Will I survive? How do I tell my loved ones? The last is the most important for many people after receiving a cancer diagnosis: I need accurate information right now.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases, with total funding up to more than $200 million over seven years if all contract options are exercised.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vincent Falanga, MD 960 Massachusetts Avenue, Fl 2, Boston, MA 02118-2690 Ph: () - | Dr Vincent Falanga, MD 725 Albany St # 8b, Shapiro Bldg., Boston, MA 02118-2526 Ph: (617) 638-7420 |
News Archive
Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.
Children and adolescents with epilepsy experience significant long-term socioeconomic consequences and higher personal health care costs. The findings come from a study that followed young epilepsy patients until 30 years of age
There's nothing more frightening than hearing the words "you have cancer" from your physician. With this diagnosis, many questions come to mind ... What's next? Will I survive? How do I tell my loved ones? The last is the most important for many people after receiving a cancer diagnosis: I need accurate information right now.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases, with total funding up to more than $200 million over seven years if all contract options are exercised.
› Verified 8 days ago
Erica Dommasch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Shapiro 2, Boston, MA 02215 Phone: 617-667-3753 | |
Dr. Chantal Louise Cotter, MB BCH BAO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
Dr. John J Croke, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Debjani Sahni, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Joseph C Kvedar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Staniford St, Suite 200, Boston, MA 02114 Phone: 617-726-2914 Fax: 617-724-2135 | |
Ryan Char Kelm, Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St # 250, Boston, MA 02114 Phone: 617-724-6960 | |
Dr. David Attar Hashemi, MD, MBA Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St, Boston, MA 02114 Phone: 617-726-2914 |